NYSE:NVTAInVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVTA stock has increased by 108.9% and is now trading at $33.11.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

InVitae Corp (NYSE:NVTA) announced its quarterly earnings results on Tuesday, August, 4th. The medical research company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.16. The medical research company had revenue of $46.20 million for the quarter, compared to analyst estimates of $39.63 million. InVitae had a negative net margin of 127.42% and a negative return on equity of 69.95%. The company's revenue for the quarter was down 14.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.54) earnings per share.
View InVitae's earnings history.

5 brokerages have issued 1-year target prices for InVitae's shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate InVitae's share price to reach $32.80 in the next twelve months. This suggests that the stock has a possible downside of 0.9%.
View analysts' price targets for InVitae.

News stories about NVTA stock have been trending neutral on Wednesday, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. InVitae earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about InVitae.

Some companies that are related to InVitae include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC) and Anpac Bio-Medical Science (ANPC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Square (SQ), Trade Desk (TTD), Shopify (SHOP), Walt Disney (DIS), salesforce.com (CRM), Twilio (TWLO) and Micron Technology (MU).

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (9.79%), Profit Investment Management LLC (0.13%), Moody Aldrich Partners LLC (0.12%), Mackay Shields LLC (0.08%), First Trust Advisors LP (0.04%) and Sigma Planning Corp (0.03%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Profit Investment Management LLC, OTA Financial Group L.P., Dupont Capital Management Corp, Focused Wealth Management Inc, and CWM LLC. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae.

NVTA stock was bought by a variety of institutional investors in the last quarter, including Mackay Shields LLC, First Trust Advisors LP, K.J. Harrison & Partners Inc, Moody Aldrich Partners LLC, Cresset Asset Management LLC, Coastal Investment Advisors Inc., ProShare Advisors LLC, and Strs Ohio.
View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $33.11.

InVitae has a market capitalization of $4.14 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]